Karen Akinsanya - Jun 7, 2021 Form 4 Insider Report for Schrodinger, Inc. (SDGR)

Role
EVP, Chief Biomedical Scientist, Head of Discovery R&D
Signature
/s/ Donald Shum, as attorney-in-fact for Karen Akinsanya
Stock symbol
SDGR
Transactions as of
Jun 7, 2021
Transactions value $
-$1,187,637
Form type
4
Date filed
6/9/2021, 05:00 PM
Next filing
Aug 17, 2021

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SDGR Stock Option (right to buy) Options Exercise $0 -6.48K -9.69% $0.00 60.4K Jun 7, 2021 Common Stock 6.48K $4.34 Direct F1, F5
transaction SDGR Stock Option (right to buy) Options Exercise $0 -10.2K -16.95% $0.00 50.2K Jun 8, 2021 Common Stock 10.2K $4.34 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.95, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.00 to $76.16, inclusive.
F5 This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.

Remarks:

EVP, Chief Biomedical Scientist, Head of Discovery R&D